What You Should Know:
- The American College of Cardiology (ACC) has published a new Concise Clinical Guidance (CCG) report, providing a comprehensive framework for clinicians to medically manage obesity using the "ever-expanding set of tools to assist patients in diagnosis, weight reduction, and CVD risk mitigation."
- The new guidance, published in the Journal of the American College of Cardiology (JACC), addresses the multiple causes of obesity and outlines a clinical
Read More
GLP-1
The Overlooked Connection Between GLP-1s, Obesity, and Eating Disorders
The false belief that people with obesity do not have eating disorders is one of the most harmful misconceptions in obesity care. In reality, individuals with obesity are at a high risk for eating disorders.
The intersection of obesity, mental health, and disordered eating is complex. As GLP-1 receptor agonists (like semaglutide and tirzepatide) become more widely used for weight management, the risk of exacerbating eating disorders must be addressed. Obesity is not just a metabolic
Read More
Omada Health Data Shows Companion Program Significantly Boosts GLP-1 Medication Persistence
What You Should Know:
- Omada Health, the virtual between-visit healthcare provider released new data demonstrating that its GLP-1 companion program significantly improves persistence rates for GLP-1 medications.
- The analysis found that members in Omada's program achieved weight loss results similar to those seen in controlled research settings, underscoring the importance of comprehensive support for individuals on these transformative medications.
- The findings provide
Read More
LucyRx and Personify Health Partner to Offer Integrated GLP-1 and Weight Management Solution for Employers
What You Should Know:
- LucyRx, an independent, next-generation pharmacy benefits manager (PBM), and Personify Health®, the company making healthier easier announced a strategic partnership to offer employers a more personalized, clinically grounded approach to GLP-1 medication management and weight care.
- The strategic collaboration will deliver an integrated solution that combines pharmacy benefit strategy with personalized support, including GLP-1-trained coaches and
Read More
Virta Health Launches Cost Guarantee for GLP-1s & Weight Loss
What You Should Know:
- Virta Health, a provider of sustainable weight loss and diabetes reversal through a nutrition-first approach, today announced industry-first cost guarantees for its weight loss program.
- These guarantees aim to eliminate financial risk for employers and health plans by ensuring Virta’s program pays for itself while also reining in the escalating costs associated with GLP-1 medications, which are reportedly rising 70–200% annually across the industry.
Read More
Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy
What You Should Know:
- Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans.
- These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual's health.
- The new insurance-based plans are available as an optional upgrade to Mochi’s existing offerings. They provide patients with access
Read More
CheqUp and WeightWatchers to Enhance GLP-1 Weight Loss Journeys in UK with Integrated Support
What You Should Know:
- CheqUp, one of the UK’s leading providers of GLP-1 based weight loss services, and WeightWatchers, the global leader in science-backed weight management announced a new partnership.
- The collaboration will combine the offerings of both organizations to benefit patients in the UK seeking sustainable weight loss through GLP-1 medication coupled with comprehensive behavioural support.
A Holistic Approach to GLP-1 Supported Weight Loss
The partnership aims
Read More
LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk
What You Should Know:
- LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
- The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD's collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer
Read More
Vida Health Data Shows Obesity Success Beyond GLP-1 Medications
What You Should Know:
- Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not require expensive GLP-1s to achieve sustainable, significant weight loss.
- Data from more than 18,000 participants demonstrates that Vida’s tailored treatment plans and commitment to responsible prescribing deliver better outcomes,
Read More
PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Treatment
What You Should Know:
- PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing treatment regimens for patients taking semaglutide (commonly known by brand names Ozempic and Wegovy) and other widely used weight-management drugs.
- Utilizing advanced artificial intelligence models, the report analyzes patient-specific genetic data to identify and quantify genetic variants that impact drug efficacy and safety, finding that up to a third of
Read More
